Quest Diagnostics Incorporated (NYSE: DGX) announced the pricing of a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036 under the company's shelf registration statement.

The diagnostic information services company expects to receive net proceeds from the offering on May 6, 2026, subject to customary closing conditions. Quest Diagnostics plans to use the proceeds for general corporate purposes, which may include debt repayment.

The company indicated it may use the funds to repay its $500 million aggregate principal amount of 3.45% senior notes scheduled to mature on June 1, 2026.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Mizuho Securities USA LLC are serving as representatives for the offering. The securities are being offered through a prospectus supplement and accompanying base prospectus.

Quest Diagnostics serves half the physicians and hospitals in the United States and employs nearly 57,000 people. The company provides diagnostic testing services to clinicians and consumers.